Chinese pharmaceutical enterprises are ramping up efforts to expand business in Southeast Asia to take advantage of favorable regulatory approval policies and mounting market opportunities.
Domestic pharmas expand in SE Asia--China Economic Net en.ce.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.ce.cn Daily Mail and Mail on Sunday newspapers.
Eyeing the huge market potential, pharmaceutical enterprises are ramping up efforts to grab a share of the COVID-19 preventative oral medicine market in China and the rest of the world.
Published: Feb 03, 2021 By Heather McKenzie
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases with a significant medical need. Here’s a look at four of them.
Illumina and Sequoia Capital China Incubating Genomics Talent
On Monday, leading DNA sequencing and array-based technologies company,
, announceda deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics.
Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.